Program
pegfilgrastim
Also written as “Pegfilgrastim”, “CHS-1701” and “QL0605(PEG-rhG-CSF)”.
Its studies are mostly in Neutropenia · Breast Neoplasms · Lymphoma, Non-Hodgkin · Lymphoma · Febrile Neutropenia, led by 21 companies.
Drug pagePegfilgrastim: every studyMany companies study it; this page follows only the 47 they lead. All 136 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 150 open or running | phase 4since Jun 21, 2005 | May 3, 2002 | none ahead |
| Dong-A STits history only | 30 open or running | phase 3since Jan 19, 2012 | Jan 19, 2012 | none ahead |
| Kyowa Kirinits history only | 30 open or running | phase 2since Aug 14, 2006 | Aug 14, 2006 | none ahead |
| Adello Biologicsits history only | 20 open or running | phase 1since Apr 12, 2017 | Apr 12, 2017 | none ahead |
| Coherus Biosciencesits history only | 20 open or running | phase 1since Apr 8, 2015 | Apr 8, 2015 | none ahead |
| Fresenius Kabiits history only | 20 open or running | phase 1since Aug 14, 2017 | Aug 14, 2017 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 20 open or running | phase 2since Aug 6, 2013 | Jul 2, 2012 | none ahead |
| Intas Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Merckleits history only | 20 open or running | phase 1since Apr 18, 2012 | Apr 18, 2012 | none ahead |
| Mundipharmaits history only | 20 open or running | phase 1since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Qilu Pharmaceuticalits history only | 21 open or running | phase 4since Sep 25, 2024 | Nov 9, 2020 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 6, 2026 | Feb 6, 2026 | none ahead |
| Coherus Oncologyits history only | 10 open or running | phase 1since Mar 2, 2015 | Mar 2, 2015 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 1since Oct 20, 2015 | Oct 20, 2015 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 3since Feb 6, 2011 | Feb 6, 2011 | none ahead |
| Gedeon Richter Plc.its history only | 10 open or running | phase 1since Apr 26, 2017 | Apr 26, 2017 | none ahead |
| Gema Biotechits history only | 10 open or running | phase 3since Feb 15, 2016 | Feb 15, 2016 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 4since May 16, 2016 | May 16, 2016 | none ahead |
| Kexing Biopharmits history only | 11 open or running | phase 3since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Nanogen Pharmaceutical Biotechnology Joint Stockits history only | 10 open or running | phase 1since Dec 12, 2017 | Dec 12, 2017 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jan 21, 2014 | Jan 21, 2014 | none ahead |
Also a collaborator on its studies: Lambda Therapeutic Research, Celerion and Symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since May 3, 2002.
- May 16, 2016Hoffmann-La Roche’s first study: phase 4 study in Lymphoma, Non-HodgkinNew to Hoffmann-La RocheHoffmann-La Roche · NCT02782845 · 53 enrolled · Colombia, Mexico
- Sep 19, 2016Phase 1 study in Healthy VolunteersMundipharma · NCT02912377 · 96 enrolled · Germany
- Oct 13, 2016Phase 1 study in LymphomaDong-A ST · NCT02963389 · 27 enrolled · Korea, Republic of
- Apr 12, 2017Adello Biologics’ first studies: 2 phase 1 studies in Healthy VolunteersNew to Adello BiologicsAdello Biologics · NCT03206229, NCT03202927
- Apr 26, 2017Gedeon Richter Plc.’s first study: phase 1 study in BioequivalenceNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT03146988 · 150 enrolled · United Kingdom
- Aug 14, 2017Fresenius Kabi’s first studies: 2 phase 1 studies in HealthyNew to Fresenius KabiFresenius Kabi · NCT03251248, NCT03251339
- Dec 12, 2017Nanogen Pharmaceutical Biotechnology Joint Stock’s first study: phase 1 study in Breast NeoplasmsNew to Nanogen Pharmaceutical Biotechnology Joint StockNanogen Pharmaceutical Biotechnology Joint Stock · NCT03376503 · 24 enrolled · Vietnam
- May 23, 2019Phase 2 study in Peripheral Blood Stem Cell TransplantationKyowa Kirin · NCT03993639 · 35 enrolled · Japan
- Jul 8, 2019Intas Pharmaceuticals’ first studies: 2 phase 1 studiesNew to Intas PharmaceuticalsIntas Pharmaceuticals · NCT04015232, NCT04014062
- Nov 9, 2020Qilu Pharmaceutical’s first study: phase 1 study in HealthyNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT04651036 · 300 enrolled · Germany, United Kingdom
- Aug 2, 2021Phase 2 study in Multiple MyelomaKyowa Kirin · NCT05007652 · 64 enrolled · Japan
- Sep 25, 2024Phase 4 study in Chemotherapy-Induced Febrile NeutropeniaQilu Pharmaceutical · NCT06616571 · 336 planned · China
- Nov 25, 2024Kexing Biopharm’s first study: phase 3 study in Chemotherapy-Induced Febrile NeutropeniaNew to Kexing BiopharmKexing Biopharm · NCT06711523 · 250 enrolled · China
- Feb 6, 2026Amneal Pharmaceuticals’ first study: phase 1 study in Healthy VolunteerNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT07416955 · 180 enrolled · United States
TargetBeta
“A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity”NCIt, by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07416955Healthy Volunteer · United States | 1 | Completed | Amneal Pharmaceuticals | Oct 10, 2025 | 180 |
| NCT06711523Chemotherapy-Induced Febrile Neutropenia · China | 3 | Active, not recruiting | Kexing Biopharm | Jun 30, 2026 | 250 |
| NCT06616571Chemotherapy-Induced Febrile Neutropenia · China | 4 | Recruiting | Qilu Pharmaceutical | Dec 30, 2025 | 336 |
| NCT05007652Multiple Myeloma · Japan | 2 | Completed | Kyowa Kirin | Oct 25, 2022 | 64 |
| NCT04651036Healthy · Germany, United Kingdom | 1 | UNKNOWN | Qilu Pharmaceutical | Nov 30, 2021 | 300 |
| NCT04015232Immunogenicity · India | 1 | Completed | Intas Pharmaceuticals | Jun 5, 2018 | 200 |
| NCT04014062Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers · India | 1 | Completed | Intas Pharmaceuticals | May 1, 2018 | 144 |
| NCT03993639Peripheral Blood Stem Cell Transplantation · Japan | 2 | Completed | Kyowa Kirin | Jul 21, 2020 | 35 |
| NCT03376503Breast Neoplasms · Vietnam | 1 | Completed | Nanogen Pharmaceutical Biotechnology Joint Stock | Oct 9, 2017 | 24 |
| NCT03251339Healthy · New Zealand | 1 | Completed | Fresenius Kabi | Feb 5, 2018 | 336 |
| NCT03251248Healthy · Australia | 1 | Completed | Fresenius Kabi | May 8, 2018 | 294 |
| NCT03146988Bioequivalence · United Kingdom | 1 | Completed | Gedeon Richter Plc. | Sep 14, 2017 | 150 |
| NCT03202927Healthy Volunteers · United States | 1 | Completed | Adello Biologics | Mar 1, 2018 | 102 |
| NCT03206229Healthy Volunteers · United States | 1 | Completed | Adello Biologics | Jun 2, 2017 | 120 |
| NCT02963389Lymphoma · Korea, Republic of | 1 | Completed | Dong-A ST | Nov 2018 | 27 |
| NCT02912377Healthy Volunteers · Germany | 1 | Completed | Mundipharma | May 2017 | 96 |
| NCT02782845Lymphoma, Non-Hodgkin · Colombia, Mexico | 4 | Completed | Hoffmann-La Roche | Oct 2007 | 53 |
| NCT03404752Breast Neoplasms · Argentina | 3 | UNKNOWN | Gema Biotech | Jun 2018 | 120 |
| NCT02650973Healthy · United States | 1 | Completed | Coherus Biosciences | Jun 2016 | 122 |
| NCT02629562Clinical Pharmacology · Germany | 1 | Completed | Mundipharma | Jul 2016 | 172 |
| NCT02589301Neutropenia · Brazil | 1 | Completed | Eurofarma Laboratorios | Mar 2016 | 100 |
| NCT02418104Immunity, Humoral · United States | 1 | Completed | Coherus Biosciences | Dec 2015 | 303 |
| NCT02385851Bioequivalence · United States | 1 | Completed | Coherus Oncology | Jul 2015 | 116 |
| NCT02306915Pharmacokinetics · United Kingdom | 1 | Completed | Merckle | Mar 2015 | 48 |
| NCT02044276Neutropenia · Germany, Italy, Spain | 3 | Completed | Teva Pharmaceutical Industries | Aug 29, 2017 | 101 |
| NCT01923545Chemotherapy Induced Neutropenia · Korea, Republic of | 2 | Completed | Dong-A ST | May 2011 | 61 |
| NCT01918241Neutropenia · China | 2 | UNKNOWN | Hangzhou Jiuyuan Gene Engineering | Jan 2016 | 200 |
| NCT01637493Neutropenia · China | 1 | UNKNOWN | Hangzhou Jiuyuan Gene Engineering | Feb 2013 | 24 |
| NCT01585649Neuroectodermal Tumors, Primitive, Peripheral · Bulgaria, Czech Republic, Hungary and more | 1 | Completed | Merckle | Jun 2014 | 21 |
| NCT01674855Chemotherapy Induced Neutropenia · Korea, Republic of | 3 | Completed | Dong-A ST | Feb 2013 | 74 |
| NCT01328938Neutropenia · Korea, Republic of | 3 | Completed | GC Biopharma | Nov 2012 | 177 |
| NCT00364468Neutropenia · Japan | 2 | Completed | Kyowa Kirin | Mar 2008 | 107 |
| NCT00277160Neutropenia | 4 | Completed | Amgen | Nov 2004 | 852 |
| NCT00261313Breast Neoplasms | 2 | Completed | Amgen | Jun 2007 | 80 |
| NCT00124111Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00117910Breast Neoplasms | 3 | Completed | Amgen | ||
| NCT00117897Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117455Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117442Breast Neoplasms | 2 | Completed | Amgen | Aug 2004 | 61 |
| NCT00115414Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00115206Carcinoma, Non-Small-Cell Lung | 4 | Completed | Amgen | ||
| NCT00115193Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | Aug 2005 | 77 |
| NCT00114764Leukemia, Myeloid | 2 | Completed | Amgen | Apr 2004 | 84 |
| NCT00094809Colonic Neoplasms | 2 | Completed | Amgen | May 19, 2006 | 252 |
| NCT00066092Lymphoma | 2 | Completed | Amgen | Mar 2004 | 41 |
| NCT00035620Sarcoma | 2 | Completed | Amgen | Jan 2007 | 44 |
| NCT00035594Neutropenia | 3 | Completed | Amgen | Feb 2004 | 928 |
How it is read
Names in the registry
- “Pegfilgrastim”, 13 entries
- “pegfilgrastim”, 12 entries
- “CHS-1701”, 3 entries
- “QL0605(PEG-rhG-CSF)”, 2 entries
- “lipegfilgrastim”, 2 entries
Codes read as this program: TPI120.
Conditions, from the studies’ own filings
- Neutropenia, 14 studies
- Breast Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 4 studies
- Lymphoma, 2 studies
- Febrile Neutropenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.